Actuate Therapeutics IPO represents a significant milestone for the company Actuate Therapeutics, US-based clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer and inflammatory diseases, has published that its IPO is going to be floated on the 13 of August 2024 and the period will end on 14 of August 2024. It aims to gather US$22.4 million with 2,800,000 shares of its common stock, with price range of US$8.00 to US$10.00. Company Overview Actuate Therapeutics Inc. is a clinical-stage bio pharmaceutical firm focusing on developing innovative therapy products for cancer and inflammation. The current lead compound, elraglusib (9-ING-41), is…
Disclaimer: Stock Market investments are subject to market risks, read all scheme related documents carefully before investing. Any financial and crypto market information in terms of articles and advertisement are written for informational purpose only and is not investment advice. Conduct your own research by contacting financial experts before making any investment decisions.